Informations générales (source: ClinicalTrials.gov)
Multicenter Protocol in Treating Patients With Childhood Acute Myeloid Leukemia. Randomized Study of Maintenance Treatment With Interleukin-2 (Elam02)
Interventional
Phase 3
Assistance Publique - Hôpitaux de Paris (Voir sur ClinicalTrials)
mars 2005
mars 2012
29 juin 2024
The purpose of this study is to evaluate the interest of maintenance treatment with
interleukin-2 by randomizing the patients being not allogeneic transplanted in complete
remission after induction and consolidation chemotherapy concerning the event free
survival.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| EFS IDF SITE ARMAND TROUSSEAU | Anne Auvrignon, M.D. | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Age: 0 to 18 years
- Prior untreated acute myeloid leukemia (AML) of following cytological types : FAB
M0, M1, M2, M4, M4 eosinophil, M5, M6, M7, without FAB classification or showing
myelodysplasia (blasts > 20 %)
- Isolated myeloid sarcoma
- Achieved complete remission
- No HLA identical family donor, except for the patients with t(8;21)
- No contraindication for the use of interleukin-2
- Age: 0 to 18 years
- Prior untreated acute myeloid leukemia (AML) of following cytological types : FAB
M0, M1, M2, M4, M4 eosinophil, M5, M6, M7, without FAB classification or showing
myelodysplasia (blasts > 20 %)
- Isolated myeloid sarcoma
- Achieved complete remission
- No HLA identical family donor, except for the patients with t(8;21)
- No contraindication for the use of interleukin-2
- Trisomy 21
- Promyelocytic leukemia (M3) or M3 variations
- Secondary AML